Maintaining Investments in New Innovation Act

Hozzl · 2025-03-28T08:07:11Z

Explore the details of House Bill 1672 Maintaining Investments in New Innovation Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/28/2025, 8:07 AM

Summary of Bill HR 1672

Bill 119 HR 1672, also known as the "Genetically Targeted Technologies Access Protection Act," aims to amend title XI of the Social Security Act in order to safeguard access to genetically targeted technologies. The bill seeks to ensure that individuals have continued access to these innovative medical technologies, which are designed to target specific genetic markers in order to provide more personalized and effective treatments.

The proposed legislation recognizes the importance of genetic testing and personalized medicine in improving healthcare outcomes for individuals with genetic conditions or predispositions. By protecting access to genetically targeted technologies, the bill aims to promote advancements in medical research and treatment options for individuals with genetic disorders.

If passed, the bill would provide regulatory oversight and guidance to ensure that genetically targeted technologies are accessible and affordable for those who need them. It would also establish mechanisms to monitor and evaluate the effectiveness of these technologies in improving health outcomes and reducing healthcare costs. Overall, Bill 119 HR 1672 seeks to support the development and utilization of genetically targeted technologies in healthcare, with the goal of improving access to personalized treatments and advancing medical innovation in the United States.

Congressional Summary of HR 1672

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 1672

Bill HR 1672 is currently in the status of Bill Introduced since February 27, 2025. Bill HR 1672 was introduced during Congress 119 and was introduced to the House on February 27, 2025. Bill HR 1672's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of February 27, 2025

Bipartisan Support of Bill HR 1672

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1672

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 1672

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

Start holding our government accountable!